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Economic evaluation of
laparoscopic surgery for
colorectal cancer
Robyn M. de Verteuil, Rodolfo A. Herna´ndez, Luke Vale
University of Aberdeen
On behalf of the Aberdeen Health Technology Assessment Group
Objectives: The aim of this study was to assess the cost-effectiveness of laparoscopic
surgery compared with open surgery for the treatment of colorectal cancer.
Methods: A Markov model was developed to model cost-effectiveness over 25 years. Data
on the clinical effectiveness of laparoscopic and open surgery for colorectal cancer were
obtained from a systematic review of the literature. Data on costs came from a systematic
review of economic evaluations and from published sources. The outcomes of the model
were presented as the incremental cost per life-year gained and using cost-effectiveness
acceptability curves to illustrate the likelihood that a treatment was cost-effective
at various threshold values for society’s willingness to pay for an additional life-year.
Results: Laparoscopic surgery was on average £300 more costly and slightly less
effective than open surgery and had a 30 percent chance of being cost-effective if society
is willing to pay £30,000 for a life-year. One interpretation of the available data suggests
equal survival and disease-free survival. Making this assumption, laparoscopic surgery
had a greater chance of being considered cost-effective. Presenting the results as
incremental cost per quality-adjusted life-year (QALY) made no difference to the results,
as utility data were poor. Evidence suggests short-term benefits after laparoscopic repair.
This benefit would have to be at least 0.01 of a QALY for laparoscopic surgery to be
considered cost-effective.
Conclusions: Laparoscopic surgery is likely to be associated with short-term quality of
life benefits, similar long-term outcomes, and an additional £300 per patient. A judgment
is required as to whether the short-term benefits are worth this extra cost.
Keywords: Cost-effectiveness, Markov modeling, Colorectal cancer, Surgery, Systematic
Review
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Colorectal cancer is one of the most common cancers in the
Western world. In the United Kingdom, it is the second most
common cancer in women and the third most common cancer
in men.
Colorectal cancer cases typically arise sporadically in
individuals over the age of 50 (12), with only a small pro-
portion of patients having a strong inherited predisposition.
Further risk factors relate to diet, body weight, physical ex-
ercise, tobacco use, and alcohol consumption (4).
Surgical resection of the cancer is the main treatment and
is almost always performed as an open surgical procedure.
Open resection involves one long incision through the ab-
dominal wall and is associated with high complication rates.
These complications include wound infection, postoperative
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pain, anastomotic leakage, urinary tract infection, and long-
term complications such as incisional hernia. Some of the
main disadvantages of open resection include incisional pain
and an often lengthy hospitalization. Laparoscopic surgery,
a minimally invasive approach, might provide an alternative.
Compared with open surgery, it is believed to offer short-term
quality of life benefits (12). Concerns over its longer-term
effectiveness and cost, however, have led to a slow up-take.
Furthermore, laparoscopic surgery is technically more com-
plicated to perform, and its success may be influenced by the
experience of the surgical team.
Laparoscopic surgery involves several small incisions to
the abdominal wall, in which ports are inserted, allowing the
surgical instruments to be manipulated. A variant is laparo-
scopically assisted resection where the bowel is accessed la-
paroscopically but then a port site incision is enlarged, which
allows the excision of the diseased tissue. Anastomosis is
then performed externally. In practical terms, laparoscopic
and laparoscopically assisted resections can be considered
comparable as the incision sizes are relatively similar (here-
after, they are collectively known as laparoscopic surgery).
This study estimated the relative cost-effectiveness of la-
paroscopic compared with open surgery for the treatment of
colorectal cancer as well as exploring the cost-effectiveness
of the different modes of surgery by stage of disease.
METHODS
Markov Model
A Markov model was constructed to estimate the long-term
costs and benefits of a cohort of typical patients for the al-
ternative surgical treatments (Figure 1). The model followed
a cohort of patients from initial operation through convales-
cence (operation state) to return to usual activities (“disease-
free” state). The patients may remain in this state until they
die or they suffer a recurrence or metastasis and therefore
have a re-operation or some other form of management. The-
oretically, the patients could move between states until they
all eventually die. For the purposes of the analysis, the cohort
of patients have been modeled for a maximum of 25 years
(the likely maximum survival for the majority of patients).
The cycle length was set at 6 months.
The main cost components included in the model were
the initial operative procedure and the costs of subsequent
re-operations or management. If a recurrence occurred and
a re-operation indicated, the patient is assumed to receive an
open procedure. Death is the only state within the model that
a patient cannot leave (it is an absorbing state).
The short-term surgical complications were principally
captured through increased operating times and longer hos-
pitalization. The risk of an emergency re-operation within
the first few weeks after surgery was explicitly modeled due
to the additional operation costs incurred. Similarly, where
the cost of managing other complications were not captured
through increased operating time and length of stay, their
probability of occurrence and cost was factored into the cost
of a state.
Derivation of Model Parameters of Clinical
Effectiveness
The strongest source of data required for each parameter
in the model was derived from a systematic review of ran-
domized controlled trials (RCTs) of the two interventions in
the treatment of colorectal cancer (12). Data on mortality,
Figure 1. Model structure.
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Table 1. All Parameters Used within the Model
Parameter Value
Distribution and values used to
define distributions Source
Baseline probabilities per cycle (6 months)
Mortality 0.03 No distribution Bonjer (2)
Recurrence 0.046 No distribution Bonjer (2)
Mortality (nonoperative cancer) 0.2 Beta: α = 5.4, β = 21.6 Benoist (1)
Emergency operation rate 0.019 Tri: IQR 0.008 to 0.034 Murray (12)
Risk of hernia 0.03 Tri: IQR 0.002 to 0.012 Winslow (21), Leung (10),
Patankar (18), Champult (5)
Re-operation rate (after recurrence) 0.05 Beta: α =15, b=285 NHS Grampian
Relative effect sizes
Mortality 1.016 Normal: 95% CI 0.958 to 1.054 Bonjer (2)
Recurrence 0.993 Normal: 95% CI 0.943 to 1.060 Bonjer (2)
Mortality (nonoperative cancer) 1 None
Emergency operation rate 1.13 Lognormal: 0.74 to 1.73 MA from SR of effectiveness (12)
Risk of hernia 1 None
Re-operation rate (after recurrence) 1 None
Costs (£) 2004
Open procedure cost including follow-up
to 3 months
5, 852 Tri: IQR 4968 to 6272 King (8)
Relative cost of laparoscopic 1.05 Log normal: SD 0.33 King (8)
Emergency operation 1, 615 Tri: IQR 1130 to 2322 NRC HRG F42 (16)
Re-operation (as open) 5, 852 Tri: IQR 4968 to 6272 King (8)
Outpatient visit 99 None King (8)
CT scan 73 Tri: IQR 56 to 91 NRC, CT (other) (16)
Colonoscopy 622 Tri: IQR 370 to 868 NRC HRG F35 (16)
Surgery for hernia 1, 689 Tri: IQR 1306 to 2234 NRC HRG F72 (16)
Nonoperative management following recurrence 1, 216 None Expert advice; costs from BNF (3)
Utilities (QALYs)
Initial operation 0.83 None Norum (17)
Disease-free 1 None
Recurrence 0.83 None Norum (17)
Disease-free (after recurrence) 1 None
Nonoperative management 0.83 None Norum (17)
Dead 0 None
Tri, triangular distribution; IQR, interquartile range; MA, meta-analysis; SR, systematic review; CI, confidence interval; SD, standard deviation; NRC,
national reference costs; HRG, health-related group; CT, computed tomography; BNF, British National Formulary; QALYs, quality-adjusted life-years.
recurrence rates, re-operation rates, emergency operations,
and the long-term risk of hernia were all taken from this
review (12). In brief, this review, an update of a previous re-
view conducted in 2000 (20), involved a systematic literature
search, restricted to the years 2000 onward. Full details of
the search strategy are available from the authors (12). All
included studies needed to meet prespecified eligibility cri-
teria. Standard meta-analysis techniques were used to obtain
overall estimates of effectiveness, where appropriate, and are
reported in detail elsewhere (12). The review included a to-
tal of forty-six reports describing twenty studies (nineteen
RCTs and one individual patient data [IPD] meta-analysis).
The IPD meta-analysis (2), synthesized data from a subset
of patients from four of the main RCTs included within the
systematic review of effectiveness; (6;7;9;19).
The risk of death and recurrence were taken from the IPD
meta-analysis (2) and were assigned a constant rate based on
consideration of the survival curves that showed a similar
rate, for both interventions (see Table 1 for parameter values
used in the model). The risk of mortality following the re-
currence of nonoperative cancer was based on data derived
from Benoist and colleagues (1). A beta distribution was
used to reflect the uncertainty in this estimate. Other base-
line parameters required for the model included the risk of
hernia, emergency re-operation for a postoperative complica-
tion, and re-operation for recurrent disease. The risk of hernia
was identified as an important long-term complication. The
severity and rates of port site hernia and incisional hernia
were included in the model. As data were sparse, it was not
possible to draw any distinction between the two types of her-
nia. The rate of hernia for open resection was derived from
the rates reported in the open arms of those trials (10;21)
identified by the systematic review of effectiveness and a
further focused search of nonrandomized studies (5;18). The
risk of hernia per cycle was estimated for each study and the
median of these was used. A triangular distribution based
on the estimated 25 and 75 percentile estimates from the
identified studies was used (Table 1).
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It was believed that the risk of emergency surgery for
most postoperative complications would be low. The one
complication for which an emergency re-operation would
generally be required was anastomotic leakage and, based
on clinical advice, the risk of an emergency re-operation was
taken to be equal to the risk of an anastomotic leakage (per-
sonal communication: Professor Z. Krukowski and Ms. A.
McKinley, 2005). The baseline risk of an anastomotic leak-
age was based on the rates reported in the open arms of
those trials identified by the systematic review of effective-
ness (12). The point estimate and distribution were defined
using the same method as described above.
Should the cancer recur, the individual might have a re-
operation but data on this were not available from any of the
included studies. Data from Grampian University Hospitals
National Health Service (NHS) Trust, however, suggested
that, of over 300 resections per year, approximately four-
teen to fifteen are re-operations (personal communication:
Professor Z. Krukowski and Ms. A. McKinley, 2005). A
beta distribution was used to reflect uncertainty of the point
estimate.
Data on relative effect sizes of laparoscopic versus open
surgery were derived from the systematic review of effective-
ness (12) and the IPD meta-analysis (2). The relative effect
size of the risk of death and recurrence for laparoscopic ver-
sus open resection were based on the interpretation of the
IPD meta-analysis (2) to provide an estimate of the relative
difference between laparoscopic and open surgery. A normal
distribution was defined using information on the confidence
interval surrounding the relative difference.
A relative risk of one was assumed for the mortality rate
for individuals with noncurative cancer as prognosis was
taken to be the same regardless of the initial method of resec-
tion (Table 1). The relative risk of an emergency operation
was based on that for anastomotic leakage, which came from
the systematic review of effectiveness (12). Based on the
confidence interval reported, a lognormal distribution was
used to define the imprecision around this estimate (Table 1).
The relative risk of hernia and the relative risk of a re-
operation after a recurrence were also required. In both cases,
a relative risk of one was assumed. In the former case, the
evidence from the review of effectiveness was limited but
there was no statistically significant difference between the
rates of both types of hernia (12). In the latter case, this was
assumed because the initial method of resection would not
affect the method of management subsequent to a recurrence.
Data on Resource Use and Cost
Total costs included initial operation costs, hospital ward
costs, and any further follow-up costs. The analysis was taken
from a UK NHS perspective and focused on direct medical
costs. Table 1 shows the estimated costs for laparoscopic and
open resection. These costs were derived using data based
on a UK RCT comparing laparoscopic with open surgery
within an enhanced recovery program (8). The follow-up
costs from this RCT were only up to 3 months and related to
a fast-track recovery program. They do not, therefore, reflect
typical length of stay estimates. These data, therefore, were
combined with more typical estimates of length of stay and
postoperative complications from the systematic review of
effectiveness (12) to estimate the operation cost incurred in
the first 6 months (i.e., the first cycle of the model). Added to
this cost were the costs of follow-up visits, based on consul-
tation with clinical experts to reflect the frequency of visits.
Costs of two potential complications were also modeled (risk
of emergency surgery and risk of incisional or port-site her-
nia). The cost per patient was the product of the probability
of those complications occurring, combined with standard
UK unit costs (16). The cost of care for those patients suffer-
ing a recurrence, where re-operation would not be indicated,
was the cost of medications used to control symptoms. These
were based on a typical drug regimen of care for a patient, de-
fined following consultation with a MacMillan Cancer Nurse
(personal communication: Flora O’Dea—Hospital Specialist
Palliative Care Team 2005) (3).
Cost-Effectiveness
The base-case analysis was based on the costs and out-
comes faced by a cohort of typical patients. Results are pre-
sented as incremental cost per additional life-year gained.
The data are also presented as cost-effectiveness acceptabil-
ity curves (CEACs), which reflect the statistical variability
in the model’s input parameters. These curves illustrate the
likelihood that a strategy is cost-effective at various thresh-
old values for society’s willingness to pay for an additional
life-year. All costs and benefits were discounted, at a rate of
6 percent for costs and 1.5 percent for benefits (13). Costs
were based on 2004 prices, and the analysis was conducted
from the perspective of the UK NHS.
Sensitivity Analysis
In addition to the probabilistic sensitivity analysis used to
generate CEACs, sensitivity analysis focused on varying
key assumptions and/or parameters in the base-case model.
Sensitivity analyses surrounding the relative survival and
disease-free survival estimates for laparoscopic resection
were performed, as they are important drivers within the
model and subject to considerable uncertainty. To further
evaluate these estimates, a second analysis using alternative
survival and disease-free survival estimates for both open
and laparoscopic patients, based on the meta-analysis of all
relevant trials was conducted (12). These estimates were ma-
nipulated to allow the mortality and recurrence rates for la-
paroscopic compared with open resection to be established
giving point estimates of 0.97 (standard deviation of 0.03)
and 0.99 (standard deviation of 0.03), respectively. Given
the nature of the data, the imprecision around the relative
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 23:4, 2007 467
de Verteuil et al.
risk was assigned a normal distribution. Further analysis also
considered the use of various quality of life estimates to esti-
mate QALYs. Sensitivity analyses surrounding the base-line
risk of hernia, mortality rates for patients with nonoperative
cancer, and rates of re-operation after recurrence were also
conducted.
RESULTS
Base-Case and Equal Survival
For the base-case model, laparoscopic is dominated by open
resection over the 25-year time horizon; that is, laparoscopic
resection is more costly and less-effective in comparison to
open resection (Table 2). One interpretation of the data pro-
vided by the IPD meta-analysis, however, is that there is no
difference between laparoscopic and open resection in terms
of survival and disease-free survival at 3 years (2). An analy-
sis assuming equal survival and disease-free survival showed
that laparoscopic resection was, again, more costly and no
more effective (Table 2). Based on these data alone, it would
be unlikely that a policy maker would recommend increas-
ing the uptake of laparoscopic surgery. The point estimates of
the incremental cost-effectiveness provided do not, however,
provide any indication of the uncertainty that surrounds the
model parameters.
Figures 2 and 3 report the CEACs comparing laparo-
scopic to open surgery in terms of life-years for the base-case
model and for the equal survival analysis. Open surgery has
a greater chance of being considered cost-effective, for the
base-case analysis, at the various threshold values of soci-
ety’s willingness to pay for a life-year. If society was willing
to pay £30,000 for a life-year then laparoscopic resection
has approximately a 30 percent chance of being considered
cost-effective (Figure 2). The results are driven by very small
differences in survival and disease-free survival estimated to
exist at 3 years follow-up. Therefore, an alternative interpre-
tation of the data on survival and disease-free survival is that
there are no meaningful differences and, in this situation,
the likelihood that laparoscopic surgery might be considered
cost-effective is greater compared with the base-case analysis
(Figure 3).
Sensitivity Analysis
Using the two pooled estimates derived for overall sur-
vival and disease-free survival from the meta-analysis re-
sulted in laparoscopic surgery being more costly (by ap-
proximately £350) but more effective, with an incremental
cost-effectiveness ratio of £1778 (Table 2 and Figure 4). This
result is as would be expected given the pooled estimates on
survival and disease-free survival used (12). This analysis
serves to highlight the sensitivity of the model to these par-
ticular parameter estimates.
Utility data, although sparse, were sought in an attempt
to capture the quality of life differences that might be appar-
ent after the two forms of resection. Data were taken from
one published study using the EQ-5D questionnaire to ob-
tain utility scores (17). On the basis of these data, it has been
assumed that the recovery from both open and laparoscopic
surgery was associated with a value of 0.83. It has also been
assumed that, by definition, the time spent free from dis-
ease was associated with a value of 1. The value associated
with the other states (except death) was also 0.83. These
Table 2. Base-Case and Sensitivity Analysis Results (Deterministic and Probabilistic)
Probability of cost-effectiveness for
different threshold values for society’s
willingness to pay for a life-year (%)
Base-case and sensitivity analysis Procedure Cost (£) 2004 Life-years ICER (£) £10,000 £20,000 £30,000 £50,000
Base-case Open 10174 15.351 61.6% 66.4% 67.6% 67.7%
Laparoscopic 10463 15.298 Dominated 38.4% 33.6% 32.4% 32.3%
Equal survival Open 10174 15.351 54.7% 54.8% 54.9% 54.2%
Laparoscopic 10490 15.351 Dominated 45.3% 45.2% 45.1% 45.8%
RR for OS and DFS from MA Open 10174 15.351 26.7% 20.4% 18.6% 18.0%
conducted as part of the
systematic review of
effectiveness (12)
Laparoscopic 10511 15.541 1778 73.3% 79.6% 81.4% 82.0%
Probability of cost-effectiveness for
different threshold values for society’s
willingness to pay for a QALY (%)
Sensitivity analysis Procedure Cost (£) 2004 QALYs ICER (£) £10,000 £20,000 £30,000 £50,000
Use of utility values to estimate Open 10174 14.679 61.0% 65.1% 65.7% 66.7%
QALYs (17) Laparoscopic 10463 14.630 Dominated 39.0% 34.9% 34.3% 33.3%
RR, relative risk; OS, overall survival; DFS, disease-free survival; MA, meta-analysis; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted
life-years.
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Figure 2. Cost-effectiveness acceptability curve showing society’s willingness to pay for a life-year for the comparison of
laparoscopic with open surgery (base-case analysis).
Figure 3. Cost-effectiveness acceptability curve showing society’s willingness to pay for a life-year for the comparison of
laparoscopic with open surgery assuming equal survival and disease-free survival.
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Figure 4. Cost-effectiveness acceptability curve showing society’s willingness to pay for a life-year for the comparison of
laparoscopic with open surgery using pooled estimates of survival and disease-free survival from the systematic review of
effectiveness (12).
utility estimates were applied to the base-case model. Both
the deterministic and probabilistic analyses are similar to the
base-case results (see Table 2).
The estimates of QALYs do not capture any potential
QALY gain that might be associated with an earlier recovery
following laparoscopic surgery. Some indication of the rele-
vance of this finding was assessed by looking at the QALY
gain required for laparoscopic surgery to be judged worth-
while. Assuming a threshold value for society’s willingness
to pay for a QALY of £30,000 (14), and given the mean
incremental cost of laparoscopic surgery of £289, then the
suggested value of the QALY gain would need to be 0.010
QALYs (approximately 3.5 days in full health).
The results from much of the other sensitivity analy-
ses were similar to the base-case results. The model was,
however, highly sensitive to changes in the relative effect
sizes associated with nonoperable cancer mortality and re-
operation rates, but there is no evidence to suggest that the
management of patients would differ between the compara-
tors. Finally consideration was given to the effect of stage
of disease on the results using data presented in the IPD
meta-analysis (2). Results were broadly similar to the base-
case analysis, although there was considerable uncertainty
surrounding parameter estimates. Further evidence on these
outcomes, therefore, is warranted.
DISCUSSION
It is likely that laparoscopic and open resection are similar
in terms of long-term survival and disease-free survival. It is
also likely that laparoscopic resection has some short-term
advantages in terms of recovery in the postoperative period
(12). When the cost-effectiveness measure was presented
in terms of either cost per life-year or QALY, laparoscopic
surgery was, on average, dominated by open surgery. These
results reflect the very small differences in overall survival
that were apparent at 3 years and also the lack of available
utility data in which to gauge the impact of earlier recovery
following laparoscopic surgery. The results would be greatly
strengthened if longer term randomized data were available.
With respect to utilities, the data available to estimate QALYs
were meager and should be treated with extreme caution.
Further work in this area is warranted to determine just what
level of QALY gain might be apparent following a shorter
postoperative recovery and in the long-term. The importance
of this can be ascertained from the fact that only a 0.01 gain
in QALYs would be necessary for laparoscopic surgery to be
considered cost-effective at a £30,000 threshold. It is quite
plausible that a gain of this magnitude might exist when it is
noted that, in a comparison between laparoscopic and open
groin hernia repair, the observed QALY gain was 0.006 (11).
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Sensitivity analyses were performed to determine the
effect of changing assumptions around the input parame-
ters of the economic model. In doing so, the probability
that laparoscopic surgery might be considered cost-effective
ranged from 30 percent to 80 percent. The analysis where
laparoscopic surgery had an 80 percent chance of being con-
sidered cost-effective was when the base-case survival and
disease-free survival estimates were replaced with the pooled
estimates taken from the systematic review of effectiveness
(12). It should be noted, however, that this pooled analysis
does not take into account any potential differential timing
of events.
There was little information on long-term wound-related
morbidities such as hernias. It is likely that the types of
hernias and subsequently the costs, management, and risk of
hernia would also be different after both forms of resection.
Because of the lack of data, however, the cost, management,
and associated risks were assumed to be the same for both
forms of surgery. A sensitivity analysis that addressed the
impact of this assumption showed little impact on results.
Similarly in relation to all costs, few data were available.
With respect to the main component of costs (the initial
operation), these were based on data from a very small UK
RCT (8). Further cost data from a larger sample would be
beneficial.
One important event associated with laparoscopic
surgery that was not modeled explicitly, owing to a lack
of useable data, was the effect of conversion. Laparoscopic
patients might be converted to open surgery for various rea-
sons. Often these patients have worse outcomes than those
not converted (12). It is unclear, however, whether patients
converted to open surgery would have experienced similar
complications regardless of which form of surgery had first
been undertaken (i.e., they were inappropriately considered
eligible for laparoscopic surgery). The effects of conversion
also relate to the level of experience of the particular sur-
geon and their team. Less experienced surgeons and surgical
teams might be expected to have a higher rate of conversion
than those who are more experienced. The level of conver-
sion (and, hence, cost-effectiveness) is likely, therefore, to be
determined not only by appropriate patient selection but also
by operator experience.
The results were sensitive to changes in the assumption
that care for recurrent disease would be the same for both
forms of surgery. There is, however, no evidence to suggest
that the management would differ between surgeries. Should
new data emerge indicating this finding, then further work to
develop this aspect of the model would be warranted.
A subgroup analysis focusing on stage of disease was
also conducted. Its results were based on very meager data
and are unreliable. Other subgroups that would be relevant to
investigate are age, gender, and cancer site, although it was
not possible to incorporate these outcomes into the model
owing to a lack of useable data. Further analysis and research
for these subgroups is warranted.
CONCLUSION
This study has explored the cost-effectiveness of laparo-
scopic surgery for colorectal cancer. This study is the first
economic evaluation, using a Markov model to predict long-
term outcomes, to be conducted within this area. Laparo-
scopic surgery is more costly and has a likelihood of be-
ing considered cost-effective of between 30 percent and 80
percent, depending on the assumptions made. The implied
valuation conducted found that, assuming a willingness to
pay threshold of £30,000, laparoscopic surgery would need
to be associated with a QALY gain of 0.01 to be considered
cost-effective. Further data are required relating to utility val-
ues to assess QALYs, longer term data with regard to survival
and disease-free survival, evidence relating to relevant sub-
groups and on the risk and value of “secondary” outcomes
such as hernias.
POLICY IMPLICATIONS
A judgment must be made as to whether the guidelines on
open surgery should change. Currently, less than 1 percent
of all colorectal cancer surgeries are performed laparoscop-
ically. Given the evidence that laparoscopic surgery appears
to have similar long-term outcomes compared with open
surgery, as well as being associated with potential short-term
benefits, there is a case to increase the current level of service
provision. On the basis of evidence presented in this study,
and other evidence, the National Institute for Health and
Clinical Excellence recommended that laparoscopic surgery
is an acceptable method of surgery for colorectal cancer in
the United Kingdom (15).
Very few surgeons or surgical teams are trained in this
particular form of surgery, and the implications for training of
increasing the number of laparoscopic resections performed
needs to be considered. Any decision that might be taken
by policy makers with regard to this change, however, must
take into consideration the extra costs associated with laparo-
scopic resection and indeed whether the probable quality of
life gains are worth this increased cost.
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